The behavioral and neurochemical effects of phencyclidine in humans and animals: Some implications for modeling psychosis

Behavioural Brain Research

Volumn 74, Issue 1-2, 1996, Pages 45-55

  Steinpreis, Rhea E ^a  

^a UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

Author keywords

Amphetamine; Behavioral effect; Neurochemical effect; Phencyclidine; Psychosis; Schizophrenia model

Indexed keywords

AMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENCYCLIDINE;

ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; HUMAN; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA;

EID: 0030057542     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-4328(95)00162-X     Document Type: Article

References (195)

1. Allen, R.M. and Young, S.J., Phencyclidine-induced psychosis, Am. J. Psychiatry, 135 (1978) 1081-1084.
2. Angrist, B.M. and Gershon, S., The phenomenology of experimentally induced amphetamine psychosis preliminary observations, Biol, Psychiatry, 2 (1970) 95-107.
3. Angrist, B.M., Lee, H.K. and Gershon, S., The antagonism of amphetamine-induced symptomology by a neuroleptic, Am. J. Psychiatry, 131 (1974) 817-819.
4. Aniline, O., Allen, R.E., Pitts, F.N., Yago, L.S. and Pitts, A.F., The urban epidemic of phencyclidine use: laboratory evidence from a public psychiatric hospital service, Biol. Psychiatry, 15 (1980) 813-817.
5. Aniline, O. and Pitts, F.N., Phencyclidine (PCP): a review and perspectives, CRC Crit. Rev. Toxicol., 10 (1982) 145-177.
6. Anis, N.A., Berry, S.C., Burton, N.R. and Lodge, D., The effects of optical isomers of ketamine on excitation of cat and rat spinal neurons by amino acids and acetylcholine, Neurosci. Lett., 29 (1983) 281-286.
7. Aronow, R., Micelli, J.N. and Done, A.K., Clinical observations during phencyclidine intoxication and treatment based on ion trapping, Natl. Inst. Drug Abuse Res. Monogr. Ser., 21 (1978) 218-228.
8. Aronstam, R.S., Albuquerque, E.X., Eldefrawi, A.T., Jim, K.F. and Triggle, D.J., Sites of action of phencyclidine, III. Interactions with muscarinic receptors, Mol. Pharmacol., 18 (1980) 179-184.
9. Baaker, M.D. and Amini, F.B., Observation on the psychotomimetic effects of Sernyl, Comprehen. Psychiatry, 2 (1961) 269.
10. Bagchi, S.P., Effects of phencyclidine on synaptosomal dopamine continuously appearing from phenylalanine: sensitivity to reserpine, Neuropharmacology, 20 (1981) 845-851.
11. Baldessarini, R.J. and Frankenburg, F.R., Clozapine. A novel antipsychotic agent, New Engl. J. Med., 324 (1991) 746-754.
12. Balster, R.L., Clinical implications of behavioral pharmacology research on phencyclidine, Natl. Inst. Drug Abuse Res. Monogr. Ser., 64 (1986) 148 162.
13. Balster, R.L., The behavioral pharmacology of phencyclidine. In H.Y. Meltzer (Ed.), Psychopharmacology: The Third Generation In Progress, Raven, New York, 1987, pp. 1573-1579.
14. Balster, R.L. and Chait, L.D., The behavioral pharmacology of phencyclidine, Clin. Toxicol., 9 (1976) 513-528.
15. Balster, R.L. and Schuster, C.R., A comparison of D-amphetamine, L-amphetamine, and methamphetamine self-administration in rhesus monkeys, Pharmacol. Biochem. Behav., 1 (1973) 67-71.
16. Banerjee, U. and Lin, G.S., On the mechanism of central action of amphetamine: the role of the catecholamines, Neuropharmacology, 12 (1973) 917-931.
17. Banerjee, U. and Lin, G.S., Time related interaction patterns of amphetamine with reserpine and other central depressants, Res. Commun. Chem. Pathol. Pharmacol., 6 (1973) 104-122.
18. Beardsley, P.M. and Balster, R.L., Evaluation of antagonists of the discriminitive stimulus and response rate effects of phencyclidine, J. Pharmacol. Exp. Ther., 244 (1988) 34-40.
19. Bederka, R., Schlemmer, F., Preston, K.L. and Davis, J.M., Neurosci. Abstr., 1 (1975) 225.
20. Bell, D.S., Comparison of amphetamine psychosis and schizophrenia, Am. J. Psychiatry, 111 (1965) 701-707.
21. Brocco, M.J., Rastogi, S.K. and McMillan, D.E., The effects of chronic phencyclidine administration on the scheduled behavior of rats, J. Exp. Ther., 226 (1983) 449 450.
22. Browne, R.G., Discriminitive stimulus properties of PCP mimetics, Natl. Inst. Drug Abuse Res. Monogr. Ser., 64 (1986) 134-147.
23. Buchsbaum, M.S., In: T. Greitz, D.H. Ingvar and L. Widen (Eds.), Metabolism of the Human Brain Studied With Positron Emission Tomography, Raven, New York, 1985, pp. 471-484.
24. Burns, S.R. and Lerner, S.E., Phencyclidine: an emerging drug problem, Clin. Toxicol., 9 (1976) 477-502.
25. Burns, S.R. and Lerner, S.E., Phencyclidine deaths, J. Am. Coll. Phys., 7 (1978) 135-141.
26. Burns, S.R., Lerner, S.E. and Corrado, R., Phencyclidine states of acute intoxication and fatalities, West. J. Med., 123 (1975) 345-349.
27. Byrd, L.D., Comparison of the behavioral effects of phencyclidine, ketamine, D-amphetamine and morphine in the squirrel monkey, J. Pharmacol. Exp. Ther., 220 (1982) 139-144.
28. Carlsson, A., Antipsychotic drugs, neurotransmitters, and schizophrenia, Am. J. Psychiatry, 135 (1978) 165-173.
29. Carlsson, A. and Lundquist, J., Effects of chlorpromazine and haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain, Acta Pharmacol., 20 (1963) 140-144.
30. Carlton, P.L. and Manowitz, P., Dopamine and schizophrenia: an analysis of the theory, Neurosci. Biobehav. Rev., 8 (1984) 137-151.
31. Carroll, M.E. and Stotz, D.C., Oral D-amphetamine and ketamine self-administration by rhesus monkeys: effects of food deprivation, J. Pharmacol Exp. Ther., 227 (1983) 28-34.
32. Castellani, S. and Adams, P.M., Acute and chronic phencyclidine effects on locomotor activity, stereotypy, and ataxia in rats, Eur. J. Pharmacol., 73 (1981) 143-154.
33. Castellani, S., Giannini, A.J. and Adams, P.M., Effects of naloxone, metenkephalin, and morphine-induced behavior in the rat, Psychopharmacology, 78 (1982) 76-80.
34. Chait, L.D. and Balster, R.L., The effects of acute and chronic phencyclidine on schedule-controlled behavior in the squirrel monkey, J. Pharmacol. Exp. Ther., 204 (1978) 77-87.
35. Chen, G., Pharmacology of 1-(1-phenylcyclohexyl) piperidine HCL, Fed. Proc., 17 (1958) 358.
36. Chen, G., Ensor, C., Russell, R. and Bohner, B., The pharmacology of (1-(phencylcyclohexyl) piperidine HC1, J. Pharmacol. Exp. Ther., 127 (1959) 241-250.
37. Chouinard, G. and Annable, L., Clozapine in the treatment of newly schizophrenic patients: a pilot study, J. Clin. Pharmacol., 16 (1976) 289.
38. Chouinard, G. and Annable, L., An early phase II clinical trial of BW234U in the treatment of acute schizophrenia in newly admitted patients, Psychopharmacology, 84 (1984) 282-284.
39. Connell, P.H., Amphetamine Psychosis, Chapman and Hill, London, 1958.
40. Crider, R., Phencyclidine: changing abuse patterns, Natl. Inst. Drug Abuse Res. Monogr. Ser., 64 (1986) 163-173.
41. Davies, B.M. and Beech, H.R., The effects of 1-arylcyclohexylamine (Sernyl) on twelve normal volunteers, J. Ment. Sci., 106 (1960) 912-924.
42. Deutch, A.Y., Moghaddam, B., Innis, R.B., Krystal, J.H., Aghajanian, G.K., Bunney, B.S. and Charney, D.S., Mechanisms of action of atypical antipsychotic drugs: implications for novel therapeutic strategies for schizophrenia, Schizophr. Res., 4 (1991) 121-156.
43. DiMaggio, D.A., Contreras, P.C., Quirion, R. and O'Donohue, T.L., Isolation and identification of an endogenous ligand for the phencyclidine receptor, Natl. Inst. Drug Abuse. Res. Monogr. Ser., 64 (1986) 24-36.
44. Dinwiddie, S.H., Drevets, W.C. and Smith, D.R., Treatment of phencyclidine-associated psychosis with ECT, Convulsive Ther., 4 (1988) 230-235.
45. Doherty, J.D., Simonvic, M., So, R. and Meltzer, H.Y., The effects of phencyclidine on dopamine synthesis and metabolism in rat striatum, Eur. J. Pharmacol., 65 (1980) 139-149.
46. Domino, E.F., Neurobiology of PCP (Sernyl): a drug with unusual spectrum of pharmacological activity, Int. Rev, Neurobiol., 6 (1964) 303-347.
47. Domino, E.F., Neurobiology of phencyclidine - an update, Natl. Inst. Drug Abuse Res. Monogr. Ser., 21 (1978) 18.
48. Domino, E.F. and Wilson, A.E., Effects of urine acidification on plasma and urine phencyclidine levels în overdosage, Clin. Pharmacol. Ther., 22 (1977) 421-424.
49. Elchizak, M.A., Murrin, L.C., Roth, R.H. and Maas, J.W., Free and conjugated dihyroxyphenylacetic acid: effect of alterations in impulse flow in rat neostriatum and frontal cortex, Psychopharmacol. Commun., 2 (1976) 411-420.
50. Ellinwood, E.H., Jr., Amphetamine psychosis: I. Description of the individuals and process, J. Nerv. Ment. Dis., 144 (1967) 273-283.
51. Ellison, G.D. and Eison, M.S., Continuous amphetamine in toxication: an animal model of acute psychotic episode, Psychol. Med., 13 (1983) 751-761.
52. Ellison, G.D., Eison, M.S. and Huberman, H.S., Stages of constant amphetamine intoxication: delayed appearance of abnormal social behaviors in rat colonies, Psychopharmacology, 56 (1978) 293-299.
53. Ereshefsky, L., Watanabe, M.D. and Tran-Johnson, T.K., Clozapine: an atypical antipsychotic agent, Clin. Pharmacol., 8 (1989) 691-709.
54. Fauman, M.A. and Fauman, B.J., The psychiatric aspects of chronic phencyclidine use: a study of chronic PCP users, Natl. Inst. Drug Abuse Res. Monogr. Ser., 21 (1978) 183-200.
55. Fauman, B.J. and Fauman, M.A., Phencyclidine abuse and crime: a psychiatric perspective, Bull. AAPL, 10 (1982) 171-176.
56. Fessier, R.G., Sturgeon, R.D. and Meltzer, H.Y., Phencyclidineinduced ipsolateral rotation in rats with unilateral 6-hydroxydopamine-induced lesions of the substantia nigra, Life Sci., 24 (1979) 1281-1288.
57. Fessler, R.G., Sturgeon, R.D. and Meltzer, H.Y., Effects of phencyclidine and methylphenidate on D-amphetamine-induced behaviors in reserpine pre-treated rats, Pharmacol. Biochem. Behav., 13 (1980) 835-842.
58. Fischer-Cornelssen, K.A., Ferner, U.J. and Steiner, H., A multifocal method for testing drugs, Arzneimittelforschung, 24 (1974) 1706-1724.
59. Flint, B.A. and Ho, I.K., Tolerance development to phencyclidine by chronic administration, Progr. Neuropsychopharmacol., 4 (1980) 233-239.
60. Freed, W.J., Weinberger, D.R., Bing, L.A. and Wyatt, R. J., Neuropharmacological studies of phencyclidine (PCP)-induced behavioral stimulation in mice, Psychopharmacology, 71 (1980) 291-297.
61. French, E.D., Effects of N-allynormetazocine (SKF 10,047), phencyclidine and other psychomotor stimulants in the rat following 6-hydroxydopamine lesion of the ventral tegmental area, Neuropharmacology, 25 (1986) 241-248.
62. French, E.D. and Ceci, A., Non-competitive N-methyl-D-aspartate antagonists are potent activators of ventral tegmental A10 dopamine neurons, Neurosci. Lett., 119 (1990) 159-162.
63. French, E.D., Ferkany, J., Abreu, M. and Levenson, S., Effects of competitive N-methyl-D-aspartate antagonists on midbrain dopamine neurons: an electrophysiological and behavioral comparison to phencyclidine, Neuropharmacology, 30 (1991) 1039-1046.
64. Galanter, M., Castaneda, R. and Ferman, J., Substance abuse among general psychiatric patients: place of presentation, diagnosis, and treatment, Am. J. Drug Alcohol Abuse, 14 (1988) 211-235.
65. Gambill, J.D. and Kornetsky, C., Effects of chronic D-amphetamine on social behavior of the rat: implications for an animal model of paranoid schizophrenia, Psychopharmacology, 50 (1976) 215-223.
66. Garey, R.E. and Heath, R.G., Effects of phencyclidine on the uptake of 3H catecholamines by rat striatal and hypothalamic synaptosomes, Life Sci., 18 (1976) 1105-1110.
67. Garey, R.E., Weisberg, L.A. and Heath, R.G., Phencyclidine: an overview, J. Psychedel. Drugs, 9 (1977) 280-285.
68. Giannini, A.J., Loisell, R.H., DiMarzio, L.R. and Giannini, M.C., Augmentation of haloperidol by ascorbic acid in phencyclidine intoxication, Am. J. Psychiatry, 144 (1987) 1207-1209.
69. Giannini, A.J., Loisell, R.H., Price, W.A. and Giannini, M.C., Chlorpromazine vs. meperidine in the treatment of phencyclidine psychosis, J. Clin. Psychiatry, 46 (1985) 52-54.
70. Gianutsos, G. and Chute, S., Pharmacological changes induced by repeated exposure to phenylethylamine, Pharmacol. Biochem. Behav., 25 (1986) 129-134.
71. Glovinsky, D., Kirch, D.G. and Wyatt, R.J., Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients, Biol. Psychiatry, 31 (1992) 968-970.
72. Goldenberg, M.M., Pharmacology for the Psychotherapist, Accelerated Development Inc., Muncie, 1990, p. 177.
73. Greenburg, B.D. and Segal, D.S., Acute and chronic behavioral interactions between phencyclidine (PCP) and amphetamine: evidence for a dopaminergic role in some PCP-induced behaviors, Pharmacol. Biochem. Behav., 23 (1985) 99-105.
74. Greifenstein, F.E., Devault, M., Yoshitake, J. and Gajewski, J.E., A study of L-arylcyclohexylamine for anesthesia, Anesth. Analg., 37 (1958) 283-294.
75. Griffith, J.D., Cavanaugh, J., Held, J. and Oates, J., Dextroam-phetamines: evaluation of psychotomimetic properties in man, Arch. Gen. Psychiatry, 26 (1972) 97-100.
76. Grover, D., Yeragani, V.K. and Keshavan, M.S., Improvement of phencyclidine-associated psychosis with ECT, J. Clin. Psychiatry, 47 (1986) 477-478.
77. Groves, P.M. and Rebec, G.V., Biochemistry and behavior: some central actions of amphetamines and antipsychotic drugs, Annu. Rev. Psychol., 27 (1976) 91-127.
78. Hertzman, M., Reba, R. and Kotlyarov, E.V., Single photon emission computed tomography in phencyclidine and related drug abuse, Am. J. Psychiatry, 147 (1990) 255-256.
79. Hitzeman, R.J., Loh, H.H. and Domino, E.F., Effect of phencyclidine on the accumulation of 14C-catecholamines formed from 14C-tyrosine, Arch. Int. Pharmacodyn., 202 (1973) 252-258.
80. Hoffmeister, F. and Goldberg, S.R., A comparison of chlorpromazine, imipramine, morphine and D-amphetamine self-administration in cocaine dependent rhesus monkeys, J. Pharmacol. Exp. Ther., 187 (1973) 8-14.
81. Iwamoto, E.T., Comparison of pharmacologic effects of N-al lylnometazocine and phencyclidine: sensitization, cross-sensitization, and opioid antagonist activity, Psychopharmacology, 89 (1986) 221-229.
82. Jain, N.C., Budd, R.D. and Budd, B., Growing abuse of phency clidine: California 'angle dust', New Engl. J. Med., 297 (1977) 673.
83. Jann, M.W., Grimsley, S.R., Gray, E.C. and Chang, W.H., Pharmacokinetics and pharmacodynamics of clozapine, Clin. Pharmacokinetics, 24 (1993) 161-176,
84. Janowsky, D.S. and Risch, C., Amphetamine psychosis and psychotic symptoms, Psychopharmacology, 65 (1979) 73-77.
85. Javitt, D.C., Negative schizophrenic symptomology and the PCP (phencyclidine) model of schizophrenia, Hillside J. Clin. Psychiatry, 9 (1987) 12-35.
86. Javitt, D.C. and Zukin, S.R., Recent advances in the phencyclidine model of schizophrenia, Am. J. Psychiatry, 148 (1991) 1301-1308.
87. Johnson, K.M. and Balster, R.L., Acute and chronic phencyclidine administration: relationship between biodispositional factors and behavioral effects, Subst. Abuse Act. Misuse, 2 (1981) 131-142.
88. Johnson, K.M. and Jones, S.M., Neuropharmacology of phencyclidine: basic mechanisms and therapeutic potential, Annu. Rev. Pharmacol. Toxicol., 30 (1990) 707-750.
89. Johnson, K.M. and Oeffinger, K.C., The effects of phencyclidine on dopamine metabolism in the mouse brain, Life Sci., 28 (1981) 361-369.
90. Johnson, K.M. and Snell, L.D., Involvement of dopaminergic, cholinergic, and glutamatergic mechanisms in the actions of phencyclidine-like drugs, Natl. Inst. Drug Abuse Res. Monogr. Ser., 64 (1986) 52-63.
91. Johnstone, M., Evans, V. and Baigel, E., Sernyl (CI-395) in clinical anaesthesia, Br. J. Anaesth., 31 (1959) 433-439.
92. Kane, J.M., Honigfeld, G., Singer, J. and the Clozaril Collaborative Study Group, Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine, Arch. Gen. Psychiatry, 45 (1988) 789-796.
93. Kaneno, S. and Shimazono, Y., Decreased in vivo [3H]spiroperidol binding in rat brain after repeated methamphetamine administration, Eur. J. Pharmacol., 72 (1981) 101-105.
94. Kieth, V.A., Mansbach, R.S. and Geyer, M.A., Failure of halo-peridol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle, Biol. Psychiatry, 30 (1991) 557-566.
95. Koek, W., Woods, J.H. and Colpaert, F.C., N-methyl-D-aspartate antagonism and phencyclidine-like activity: a drug discrimination analysis, J. Pharmacol. Exp. Ther., 253 (1990) 1017-11025.
96. Koek, W., Woods, J.H. and Winger, G.D., MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeons, rats and rhesus monkeys, J. Pharmacol. Exp. Ther., 245 (1988) 969-974.
97. Kokkinidis, L., Effects of chronic intermittent and continuous amphetamine administration on acoustic startle, Pharmacol. Biochem. Behav., 20 (1984) 367-372.
98. Kokkinidis, L., Sensitization to amphetamine and tolerance to cocaine and phencyclidine stimulation in mice, Pharmacol Biochem. Behav., 25 (1986) 1175-1180.
99. Kokkinidis, L. and Annisman, H., Amphetamine models of paranoid schizophrenia: an overview and elaboration of animal experimentation, Psych. Bull., 88 (1980) 551-579.
100. Kolb, B. and Wishaw, I.Q., Performance of schizophrenic patients on tests of right frontal, temporal or parietal functioning in neurological patients, J. Nerv. Ment. Dis., 171 (1983) 435-443.
101. Kotz, A. and Merkel, P., Hydromatic alkamines, J. Fuer Prakt. Chem., 113 (1926) 49-76.
102. Landauer, M.R. and Balster, R.L., Opiate effects on social investigatory behavior of male mice, Pharmacol. Biochem. Behav., 17 (1982) 1181-1186.
103. Largent, B.L., Gundlach, A.L. and Snyder, S.H., Pharmacological and autoradiographic discrimination of sigma and phencyclidine receptor binding sites in brain with (+)-[3H]SKF 10,047, (+)-[3H]-3-[3-hydroxyphenyl]N-(1-propyl)piperidine and [3H]-1-[1-(2-thienyl)cyclohexy]-piperidine, J. Pharmacol. Exp. Ther., 238 (1986) 739-748.
104. Largent, B.L., Wikstrom, H., Snowman, A.M. and Snyder, S.H., Novel antipsychotic drugs share high affinity for sigma receptors, Eur. J. Pharmacol, 155 (1988) 345-347.
105. Lerner, M.S. and Burns, R.S., Phencyclidine use among youth: History, epidemiology and acute and chronic intoxication, Natl. Inst. Drug Abuse Res. Monogr. Ser., 21 (1978) 61-118.
106. Leonard, B.E. and Tongue, S.R., Some effects of hallucinogenic drug (phencyclidine) on neurohumoral substances, Life Sci., 9 (1970) 1141-1152.
107. Liden, C.B., Lovejoy, F.H. and Costello, C.F., Phencyclidine: Nine cases of poisoning, J. Am. Med. Assoc., 234 (1975) 513-516.
108. Lidow, M.S. and Goldman-Rakic, P.S., A common action of clozapine, haloperidol and remoxipride on D1-and D2-dopaminergic receptors in the primate cerebral cortex, Proc. Natl. Acad. Sci. USA, in press.
109. Lindvall, O., Bjorklund, A., Moore, R.Y. and Stenevi, U., Mesencephalic dopamine neurons projecting to neocortex, Brain Res., 81 (1974) 325-331.
110. Lindstrom, L.H., The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years, Acta Psychiatr. Scand., 75 (1987) 945-952.
111. Lodge, D., Anis, N.A. and Burton, N.R., The dissociative anesthetics ketamine and phencyclidine selectively reduce excitation of central mammalian neurons by N-methyl-aspartate, Br. J. Pharmacol., 79 (1982) 565-575.
112. Lozovsky, D., Saller, C.F., Bayorh, M.A., Chiueh, C.C., Rice, K.C., Burke, T.R., Jr. and Kopin, I.J., Effects of phencyclidine on rat prolactin, dopamine receptor and locomotor activity, Life Sci., 32 (1983) 2725-2731.
113. Luby, E.D., Cohen, B.O., Rosenbaum, G., Gottlieb, J.S. and Kelley, R., Study of a new schizophrenimetic drug - sernyl, Am. Med. Assoc. Arch. Neurol. Psychiatry, 119 (1959) 61-67.
114. Luisada, P.V., The phencyclidine psychosis: phenomenology and treatment, Natl. Inst. Drug Abuse Res. Monogr. Ser., 21 (1978) 241-253.
115. Luisada, P.V. and Brown, B.I., Clinical Management of the phencyclidine psychosis, Clin. Toxicol., 9 (1976) 539-545.
116. Maayani, S., Weinstein, H., Ben-Zvi, N., Cohen, S. and Sokolovsky, M., Psychotomimetics as anticholinergic agents, I. 1-cyclohexylpiperidine derivatives: anticholinesterase activity and antagonistic activity to acetylcholine, Biochem. Pharmacol., 23 (1974) 1263-1281.
117. MacLeod, W.D., Green, D.E. and Seet, E., Automated analysis of phencyclidine in urine by probability based matching GC/MS, Clin. Toxicol., 9 (1976) 561-572.
118. Marek, P., Chapman, C.D. and Howard, S., The effect of phencyclidine and DL-2-amino-5-phosphonovaleric acid on N-methylD-aspartic acid induced changes in extracellular concentration of dopamine and dopac in the rat neostriatum, Neuropharmacology, 31 (1992) 123-127.
119. Marshall, B. and Wollman, H., General anesthetics. In: A.G. Gliman, L.S. Goodman, T.W. Rall and F. Murad (Eds.), The Pharmacological Basis of Therapeutics, MacMillan, New York, 1985, pp. 276-301.
120. Martres, M.P., Constentin, J., Baudry, M., Marcais, H., Protais, P. and Schwartz, J.C., Long-term changes in the sensitivity of pre-and post-synaptic dopamine receptors in mouse striatum evidenced by behavioral and biochemical studies, Brain Res., 136 (1977) 319-337.
121. Mattia, A., Leccese, A.P., Marquis, K.L., El-Fakahany, E.E. and Moreton, J.E., Electroencephalographic (EEG), psychopharmacological, and receptor-binding profiles of 'phencycloids', Natl. Inst. Drug Abuse Res. Monogr. Ser., 64 (1986) 94-111.
122. McCullough, L.D. and Salamone, J.D., Increases in extracellular dopamine levels and locomotor activity after direct infusion of phencyclidine into the nucleus accumbens, Brain Res., 577 (1992) 1-9.
123. Mendelsohn, L.G., Kercher, G.A., Kalra, V., Zimmerman, D.M. and Leander, J.D., Phencyclidine receptors in rat brain cortex, Biochem. Pharmacol., 33 (1984) 3529-3535.
124. Miczek, K.A. and Yoshimura, H., Disruption of primate social behavior by D-amphetamine and cocaine: differential antagonism by antipsychotics, Psychopharmacology, 76 (1982) 163-171.
125. Misra, A.L., Pontani, R.B. and Bartolomeo, J., Persistent of phencyclidine (PCP) and metabolites in brain and adipose tissue and implications for long-lasting behavioral effects, Res. Commun. Chem. Pathol. Pharmacol., 24 (1979) 431.
126. Muller, H.F., Prefrontal cortex dysfunction as a common factor in psychosis, Acta Psychiat. Scand., 71 (1985) 431-437.
127. Murray, T.F., The effects of phencyclidine on operant behavior in the rat: biphasic effect and tolerance development, Life Sci., 22 (1978) 195-202.
128. Murray, T.F. and Horita, A., Phencyclidine-induced stereotyped behavior in rats: dose response effects and antagonism by neuroleptics, Life Sci., 24 (1979) 2217.
129. Naber, D. and Hippius, H., The European experience with clozapine, Hosp. Community Psychiatry, 41 (1990) 886-890.
130. Nabeshima, T., Sivam, S.P., Tai, C.Y. and Ho, I.K., Development of dispositional tolerance to phencyclidine by osmotic minipump in the mouse, J. Pharmacol. Methods, 7 (1982) 239-253.
131. Nabeshima, T., Yamaguchi, K., Yamada, K., Hiramatsu, M., Furukawa, H. and Kameyama, T., Serotonergic involvement in phencyclidine-induced behaviors, Pharmacol. Biochem. Behav., 21 (1984) 401-408.
132. Nakki, R., Noble, L.J., Koistinaho, J., Sharp, F.R. and Sagar, S.M., Cerebellar toxicity of phencyclidine, Soc. Neurosci. Abstr., 19 (1993) 1697.
133. Nicholi, A.M., Phencyclidine hydrochloride (PCP) use among college students: subjective and clinical effects, J. Am. Coll. Health, 32 (1984) 197-200.
134. Nogochi, T.T. and Nakamura, G.R., Phencyclidine-related deaths in Los Angeles County, J. Forensic Sci., 23 (1978) 503.
135. Olney, J.W., Farber, N.B., Price, M.T., Labruyere, J., Nemech, J. and St. Peter, H., Anti-psychotic agents prevent NMDA antagonist neurotoxicity, Soc. Neurosci. Abstr., 19 (1993) 1697.
136. Perry, D.C., PCP revisited, Pharmacol. Chem. Newslett., 4 (1975) 9.
137. Petersen, R.C. and Stillman, R.C., Phencyclidine: an overview, Natl. Inst. Drug Abuse Res. Monogr. Ser., 21 (1978) 1-17.
138. Pfefferbaum, A., Lim, K.O., Rosenbloom, M. and Zipursky, R.B., Brain magnetic resonance imaging: approaches for investigating schizophrenia, Schizophr. Bull., 16 (1990) 453-476.
139. Piercy, M.F. and Ray, C.A., Dramatic limbic and cortical effects mediated by high affinity PCP receptors, Life Sci., 43 (1988) 379-385.
140. Pinchasi, I., Maayani, S. and Sokolovsky, M., On the interaction of drugs with the cholinergic nervous system. I. Tolerance to phencyclidine derivatives in mice: pharmacologic characterization, Psychopharmacology, 56 (1977) 27-36.
141. Poling, A., Cleary, J., Jackson, K. and Wallace, S., D-Amphet amine and phencyclidine alone and in combination: effects on fixed-ratio and interresponse-time greater than-t responding in rats, Pharmacol. Biochem. Behav., 15 (1981) 357-361.
142. Poling, A.D., White, F.J. and Appel, J. B., Discriminative stimulus properties of phencyclidine, Neuropharmacology, 18 (1979) 459-463.
143. Predy, P.A. and Kokkinidis, L., Sensitization to the effects of repeated amphetamine administration on intracranial self-stimulation: evidence for changes in reward, Behav. Brain Res., 13 (1984) 251-259.
144. Ranje, C. and Ungerstedt, U., Chronic amphetamine treatment: vast individual differences in performing a learned response, Eur. J. Pharmacol., 29 (1974) 307-311.
145. Rech, R.H., Antagonism of reserpine behavioral depression by D-amphetamine, J. Pharmacol. Exp. Ther., 146 (1964) 369-376.
146. Robertson, H.A. and Mogenson, G.J., Facilitation of self-stimulation of the prefrontal cortex in rats following chronic administration of spiroperidol or amphetamine, Psychopharmacology, 65 (1979) 149-154.
147. Robinson, T.E., Becker, J.B., Moore, C.J., Castaneda, E. and Mittleman, G., Enduring enhancement in frontal cortex dopamine utilization in an animal model of amphetamine psychosis, Brain Res., 343 (1985) 374-377.
148. Sandler, M. and Reynolds, G.P., Does phenylethylamine cause schizophrenia?, Lancet, 1 (1976) 70-71.
149. Schiorring, E., Changes in individual and social behavior induced by amphetamine and related compounds in monkeys and man. In: E.H. Ellinwood and M. Kilbey (Eds.), Cocaine and Other Stimulants, Plenum, New York, 1977, pp. 481-522.
150. Schlemmer, R.F., Jackson, J.A., Preston, K.L., Bederka, J.P., Garver, D.L. and Davis, J.M., Behavioral evidence of the interaction of phencyclidine with catecholamines in primate social colonies, Fed. Proc., 35 (1976) 208.
151. Scraggs, P.R. and Ridley, R.M., The effects of dopamine and noradrenaline blockade on amphetamine-induced behavior in the marmoset, Psychopharmacology, 62 (1979) 41-45.
152. Segal, D.S. and Janowsky, D.S., Psychostimulant-induced behavioral effects: possible models of schizophrenia. In: M.A. Lipton, A. DiMascio and K.F. Killam (Eds.), Psychopharmacology. A Generation of Progress, Raven, New York, 1978, pp. 113-1123.
153. Shannon, H.E., Evaluation of phencyclidine analogues on the basis of the discriminative stimulus properties in the rat, J. Pharmacol. Exp. Ther., 21 (1981) 543-551.
154. Sharp, T., Ljungberg, T., Zetterstrom, T. and Ungerstedt, U., Intracerebral dialysis coupled to a novel activity box - a method to monitor dopamine release during behavior, Pharmacol. Biochem. Behav., 24 (1986) 1755-1760.
155. Shore, P.A., Actions of amfonelic acid and other non-amphetamine stimulants on the dopamine neuron, J. Pharm. Pharmacol., 28 (1976) 855-857.
156. Showalter, V.C. and Thornton, W.E., Clinical pharmacology of phencyclidine toxicity, Am. J. Psychiatry, 134 (1977) 1234-1238.
157. Sicar, R. and Zukin, S.R., Characterization of specific sigma opiate/phencyclidine (PCP) binding sites in the human brain, Life Sci., 33 (1983) 259-262.
158. Siegel, R.K., Phencyclidine, criminal behavior and the defenses of diminished capacity, Natl. Inst. Drug Abuse Res. Monogr. Ser., 21 (1978) 272-288.
159. Slater, E., Amphetamine psychosis, Br. Med. J., 1 (1959) 488.
160. Smith, D.E., A clinical approach to the treatment of phencyclidine (PCP) abuse, Psychopharmacol. Bull., 16 (1980) 67-70.
161. Smith, D.E., Meltzer, H.Y., Arora, R.C. and Davis, J.M., Effects of phencyclidine on 3H-catecholamines and 3H-serotonin uptake in synaptosomal preparations from rat brain, Biochem. Pharmacol., 26 (1977) 1435-1439.
162. Smith, D.E., Wesson, D.R. and Boxton, M.E., The diagnosis and treatment of PCP abuse syndrome, Natl. Inst. Drug Abuse Res. Monogr. Ser., 21 (1978) 229-240.
163. Snell, L.D. and Johnson, K.M., Characterization of the inhibition excitatory amino acid-induced neurotransmitter release in the rat striatum by phencyclidine-like drugs, J. Pharmacol. Exp. Ther., 238 (1986) 938.
164. Snell, L.D., Yi, S. and Johnson, K.M., Comparison of the effects of MK-801 and phencyclidine on catecholamine uptake and NMDA-induced norepinephrine release, Eur. J. Pharmacol., 145 (1988) 223-226.
165. Snyder, S.H., Amphetamine psychosis: a 'model' schizophrenia mediated by catecholamines, Am. J. Psychiatry, 130 (1973) 61-67.
166. Snyder, S.H., Psychotogenic drugs as models of schizophrenia, Neuropsychopharmacology, 1 (1988) 197-199.
167. Sonders, Keana and Weber, E., Recent insights into their biochemical and physiological sites of action, Trends Neurosci., 11 (1988) 37-40.
168. Steinpreis, R.E. and Salamone, J.D., The role of nucleus accumbens dopamine in the neurochemical and behavioral effects of PCP: a microdialysis and behavioral study, Brain Res., 612 (1993) 263-270.
169. Steinpreis, R.E., Sokolowski, J.D., Papanikolou, A. and Salamone, J.D., Repeated administration and partial neuroleptic reversal of PCP and amphetamine, Presented at the 1992 American Psychological Association Conference in Washington, DC.
170. Steinpreis, R.E., Sokowlowski, J.D., Papanikolau, A. and Salamone, J.D., The effects of haloperidol and clozapine on PCP-and amphetamine-induced changes in social behavior in the rat: a behavioral assay for testing novel neuroleptics, Pharmacol. Biochem. Behav., 47, (1994) 579-585.
171. Sturgeon, R.D., Fessier, R.G., Meltzer, H.Y., Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats, Eur. J. Pharmacol., 59 (1979) 169-179.
172. Swerdlow, N.R. and Koob, S.F., Dopamine, schizophrenia, mania and depression: toward a unified hypothesis of corticostriato-pallido-thalamic function, Behav. Brain Res., 10 (1987) 197-245.
173. Tam, S.W., Hethylketocyclazocine, kappa, delta and phencyclidine binding sites in the guinea pig brain membranes, Eur. J. Pharmacol., 109 (1985) 33-41.
174. Tanii, Y., Nishikawa, T. Umino, A. and Takahashi, K., Phencyclidine increases extracellular dopamine metabolites in rat medial frontal cortex as measured by in vivo dialysis, Neurosci. Lett., 112 (1990) 318-323.
175. Thierry, A.M., Blanc, G., Sobel, A., Stinus, L. and Glowinski, J., Dopaminergic terminals in the rat cortex, Science, 182 (1972) 499-501.
176. Thierry, A.M., Stinus, L., Blanc, G. and Glowinski, J., Some evidence for the existence of dopaminergic neurons in the rat cortex, Brain Res., 59 (1973) 230-234.
177. Thompson, D.M. and Moerschbaecher, J.M., Phencyclidine in combination with D-amphetamine: differential effects on acquisition and performance of response chains in monkeys, Pharmacol. Biochem. Behav., 20 (1984) 619-627.
178. Troupin, S.A., Mendius, J.R., Cheng, F. and Risinger, M.W. In: B.S. Meldrum and R.J. Porter (Eds.), Current Problems In Epilepsy: New Anticonvulsant Drugs, Libbey, London, 1986, pp. 191-202.
179. Varipap, R.J., PCP treatment, Clin. Toxicol., 10 (1977) 353-355.
180. Verebey, K., Kogan, M.J., Mule, S.J. et al., Phencyclidine induced stereotypy in rats: effects of methadone, apomorphine and naloxone, Psychopharmacology, 75 (1981) 44-47.
181. Vickroy, T.W. and Johnson, K.M., Stimulation of synaptosomal tyrosine hydroxylation by phencyclidine in vitro, Eur. J. Pharmacol., 71 (1981) 463-473.
182. Vickroy, T.W. and Johnson, K.M., Similar dopamine releasing effects of phencyclidine and nonamphetamine stimulants in striatal slices, J. Pharmacol. Exp. Ther., 223 (1982) 669-674.
183. Vickroy, T.W. and Johnson, K.M., Effects of phencyclidine on the release and synthesis of newly formed dopamine, Neuropharmacology, 22 (1983) 839-842.
184. Vincent, J.P., Cavey, D., Kamenka, Geneste, P. and Lazdunski, M., Interaction of phencyclidine with the muscarinic and opiate receptors in the central nervous system, Brain Res., 152 (1978) 176-182.
185. Vincent, J.P., Kartalouski, B., Geneste, P., Kamenka, J.M. and Lasdunski, M., Interaction of phencyclidine ('angel dust') with a specific receptor in rat brain membranes, Proc. Natl, Acad. Sci. USA, 76 (1985) 4678-4682.
186. Wachi, M., Okuda, M.K., Togashi, S., Fuwano, S. and Miyashita, O., Effects of phencyclidine administration on behavior and brain neurotensin-like immuno-reactivity in rats, Brain Res., 333 (1985) 393-396.
187. Wagner, G.C., Tsigas, D.J. and Masters, D.B., Tolerance following the repeated administration of high doses of phencyclidine: No relation to central catecholamine depletion, Drug Alcohol Depend., 13 (1984) 225-234.
188. Wang, T. and French, E.D., Effects of phencyclidine on spontaneous and excitatory amino acid-induced activity of ventral tegmental dopamine neurons: an extracellular in vitro study, Life Sci., 53 (1993) 49-56.
189. Wenger, G.R., The effects of phencyclidine, ketamine, amphetamine and pentobarbital on schedule-controlled behavior in the mouse, J. Pharmacol. Exp. Ther., 196 (1981) 616-624.
190. Willets, J. and Balster, R.L., Phencyclidine-like discriminative stimulus effects of N-methyl-D-aspartate antagonists, J. Pharmacol. Exp. Ther., 249 (1988a) 438-443.
191. Woolverton, W.L. and Balster, R.L., Tolerance to the behavioral effects of phencyclidine: the importance of behavioral and pharmacological variables, Psychopharmacology, 64 (1979) 19.
192. Yago, K.B., Pitts, F.N., Burgoyne, R.W., Aniline, O., Yago, L. and Pitts, A.F., The urban epidemic of phencyclidine (PCP) use: clinical and laboratory evidence from a public psychiatric hospital emergency service, J. Clin. Psychiatry, 42 (1981) 193-196.
193. Yesavage, J. and Freeman, A.M., Letter, Am. J. Psychiatry, 136 (1979) 235-236.
194. Young, D. and Scoville, W.B., Paranoid psychosis in narcolepsy and the possible danger of benzedrine treatment, Med. Clin. North Am., 22 (1938) 637-646.
195. Zukin, S.R. and Zukin, R.S., Specific [3H] phencyclidine binding in the rat central nervous system, Proc. Natl. Acad. Sci. USA, 76 (1979) 5372-5376.